Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other Working Capital Changes (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Other Working Capital Changes for 10 consecutive years, with -$334000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 85.35% to -$334000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.8 million through Dec 2025, down 15.09% year-over-year, with the annual reading at $32128.0 for FY2025, 62.31% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$334000.0 at Rein Therapeutics, down from $32128.0 in the prior quarter.
  • The five-year high for Other Working Capital Changes was $538000.0 in Q4 2022, with the low at -$2.3 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is -$126953.8, with a median of $5000.0 recorded in 2021.
  • Peak annual rise in Other Working Capital Changes hit 1219.35% in 2022, while the deepest fall reached 15100.0% in 2022.
  • Over 5 years, Other Working Capital Changes stood at $267000.0 in 2021, then skyrocketed by 101.5% to $538000.0 in 2022, then plummeted by 117.29% to -$93000.0 in 2023, then plummeted by 2351.61% to -$2.3 million in 2024, then surged by 85.35% to -$334000.0 in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$334000.0, $32128.0, and $23596.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.